Lessons from Novo Nordisk.

What Novo Nordisk’s $1.3B Semaglutide deal teaches MedTech about the dual business case for prevention

The healthcare industry is witnessing a quiet but profound paradigm shift. Recently, Novo Nordisk announced a deal worth up to €1.165 billion ($1.33 billion) with Swedish drug-delivery company Nanexa to develop longer-acting injectable treatments for obesity, Type 2 diabetes, and cardio-metabolic diseases. While headlines often fixate on the clinical mechanics of GLP-1 therapies like semaglutide, the deeper strategic takeaway is far more significant for the entire ecosystem: there is now an undeniable, multi-billion-dollar business case for healthcare prevention.

Crucially, this business case is no longer confined to traditional payer-provider models. It is increasingly driven by a powerful, direct-to-consumer (DTC) and over-the-counter (OTC) market, where individuals are actively choosing to invest out of pocket in their own preventive health.

The Semaglutide precedent: a dual-track value driver

Semaglutide has evolved from a metabolic management tool into a proven cardiovascular prevention therapy. Clinical evidence, most notably from the SELECT trial, demonstrates that it significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with overweight or obesity and prevalent cardiovascular disease.

While this creates a compelling Health Technology Assessment (HTA) narrative for health systems (averting costly acute events), the market reality is even more striking. A massive portion of the GLP-1 boom is fuelled by out-of-pocket consumer spending. Patients are voting with their wallets, demonstrating a clear willingness to pay directly for treatments that promise longevity, health span, and proactive disease prevention, even before insurance mandates catch up. The business case for prevention is being validated simultaneously by health economists and by consumers opening their check books.

The MedTech imperative: capturing the consumer prevention market

If pharmaceutical giants can build massive financial models around preventive cardio-metabolic care, MedTech vendors must urgently follow suit across both systemic and consumer channels. The question is no longer if prevention is valuable, but how to capture value in a market where consumers are increasingly prepared to self-fund their health.

MedTech companies would do well to identify and develop robust SRoI+ business cases for over-the-counter (OTC) and direct-to-consumer (DTC) cardiac and metabolic prevention solutions. Consider where technology can meet the consumer’s desire for proactive health management:

• Consumer wearables & at-home diagnostics: FDA-cleared or CE-marked smartwatches, portable ECGs, and continuous glucose monitors (CGMs) that empower individuals to track their cardiac and metabolic health at home, bypassing traditional clinical bottlenecks.
• Digital prevention & longevity platforms: Scalable, tech-enabled lifestyle and risk-factor management apps that offer personalized, AI-driven insights. Consumers are increasingly willing to pay subscription fees for tools that help them avoid disease and optimize their daily health.
• Hospital-at-Home & remote monitoring: While these have strong institutional SRoI+ cases, they also appeal to consumers who value the convenience, comfort, and autonomy of managing their recovery or chronic conditions outside traditional clinical settings.

Building the dual business case: SRoI+ meets consumer Willingness-to-Pay

To win in this new landscape, MedTech vendors must articulate a two-sided value proposition:

• The healthcare SRoI+ case (systemic): For providers, insurers, and policymakers, quantify clinical efficacy, capacity management, and long-term cost avoidance. How does your solution improve patient flow, reduce administrative burden, and keep individuals safely out of acute care settings?
• The out-of-pocket case (consumer): For the individual, articulate the direct, tangible value. Focus on convenience, peace of mind, health span extension, and seamless user experience. Why is this solution worth the consumer’s discretionary income?

By framing innovations through this dual lens, MedTech companies can align their value propositions with both the strategic priorities of healthcare leadership and the immediate, personal desires of the modern health consumer.

Conclusion: co-intelligence for a preventive future

For MedTech innovators, the blueprint is clear. Look at the data, identify the preventive leverage points in cardiac and metabolic care, and build a business case that proves your technology is a force for good. Whether that value is captured through systemic SRoI+ metrics or through consumers willingly investing in over-the-counter solutions, the future of healthcare is undeniably preventive.

At Care IQ, we believe that blending human intelligence with AI (co-intelligence) is the key to unlocking these next-generation preventive care models. The Novo Nordisk deal serves as a clarion call: the market increasingly rewards solutions that keep people healthy.

Are you building the next generation of preventive care technology? Let’s connect and explore how data-led strategies can strengthen both your systemic and consumer business cases.

About Care IQ: We blend co-intelligence (IQ + AI) to drive healthcare innovation, specialising in SRoI+ business cases, capacity management, and future-oriented care models that empower health systems, providers, and proactive individuals alike.

Ask us how AI and Care IQ can help.

Source: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2852962